Byron Lam, MD
Neuro-ophthalmology · Miami, FLNPI 1518982727
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $84,356 of the $85,910 with a category attached, or 98.2%. 7 manufacturers reported payments, led by Janssen Global Services, LLC at 45.2% of the total. Reporting peaked in 2020 at $27,854 and has fallen 90.1% since, to $2,747 in 2025.
Across 59 payments — averaging $1456.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Global Services, LLC$39K
- Biogen$38K
- AbbVie$4K
- Insmed, Inc.$2K
- Argenx US, Inc.$2K
- Spark Therapeutics, Inc.$239
- plus $165 from 1 others
Across 52 payments — averaging $84,693 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$4.2M
- Janssen Research & Development, LLC$63K
- Spark Therapeutics, Inc.$44K
- AbbVie$41K
- Novartis$11K
What the payments were for
- Consulting fees$84,35698%
- Travel & lodging$8401%
- Food & beverage$7141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Global Services, LLC | 30 | $38,808 |
| Biogen | 13 | $38,078 |
| AbbVie(2 entities) | 4 | $4,443 |
| Insmed, Inc. | 2 | $2,377 |
| Argenx US, Inc. | 1 | $1,800 |
| Spark Therapeutics, Inc. | 4 | $239 |
| Janssen Research & Development, LLC | 5 | $165 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$1,800
How this compares
Too few neuro-ophthalmology providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pyridostigmine Bromide | 48 | $5,421 |
| Acetazolamide ErAcetazolamide | 20 | $1,689 |
| Prednisone | 137 | $953 |
| Latanoprost | 86 | $647 |
| Azathioprine | 19 | $405 |
| Dorzolamide Hcl | 14 | $213 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $189 |
Paid to pharmacies, not to this prescriber.
Other neuro-ophthalmology in Miami
- Carlos Mendoza SantiestebanMiami$3K
- Hong JiangMiami$508
- Pablo RavennaMiami$104
- Daniela TeijeloMiami$62
- Bryan RiggealJacksonville$20K
- Hazem SamyJacksonville$6K
- David AuerbachMaitland$6K
- Shauna BerryBonita Springs$2K
- Bryce BuchowiczGainesville$394
- Aishwarya SriramTampa$371
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.